Stakeholders Interviewed Primary interviews for this study involved: Manufacturers and suppliers in the market value chain Distributors, channel partners, and integrators End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market) Industry experts, technology specialists, consultants, and regulatory professionals Senior executives (CEOs, CTOs, VPs, Directors) and product managers Interview Process Interviews were conducted via: Structured and semi-structured questionnaires Telephonic and video interactions Email correspondences Expert consultation sessions Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation
Every compounded provider on this list sources from state-licensed 503A pharmacies, the only compliant compounding path since the FDA ended the semaglutide shortage on February 21, 2025
The Coverage Landscape Medicare: Medicare Part D was prohibited by law from covering obesity medications
They are prepared by compounding pharmacies under a valid prescription
Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue
Brain Res